Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ONCY with free AI briefings, catalyst countdowns, and dilution alerts.

ONCY · Oncolytics Biotech Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$2.4M Cash on Hand
1mo Cash Runway
6.8% Short Interest
$4.42 Analyst Target (5)
Follow ONCY by email Get an email when ONCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ONCY, unsubscribe in one click. Privacy

📣 What ONCY Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Pelareorep Carcinoma, Squamous Cell of the Head and Neck Phase 3 · NCT01166542 Completed
Trifluridine and Tipiracil Hydrochloride Anal Cancer Metastatic Phase 1/2 · NCT07280377 Active not recruiting
mFOLFIRINOX Treatment Regimen Anal Cancer Metastatic Phase 1/2 · NCT07280377 Active not recruiting
Nab-paclitaxel Anal Cancer Metastatic Phase 1/2 · NCT07280377 Active not recruiting
FOLFIRI Ras-mutated Metastatic Colorectal Cancer Phase 2 · NCT07446322 Recruiting
Fluorouracil Pancreatic Adenocarcinoma Phase 1 · NCT02620423 Completed
Cytotoxic Chemotherapeutic Agent Pancreatic Adenocarcinoma Phase 1 · NCT02620423 Completed
Lenalidomide or Pomalidomide Multiple Myeloma Phase 1 · NCT03015922 Unknown
Irinotecan KRAS Mutant Metastatic Colorectal Cancer Phase 1 · NCT01274624 Completed

Also used in these trials (approved or third-party drugs, not ONCY's own candidates): Carboplatin, Paclitaxel, Atezolizumab, Retifanlimab, Pemetrexed Disodium, Gemcitabine Hydrochloride, Bevacizumab, Docetaxel Anhydrous, Avelumab, Dexamethasone, Bortezomib, Carfilzomib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ONCY holds $2.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.5M/quarter from operations, an estimated runway of 1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ONCY files for a raise →

👥 Who Owns ONCY

Insiders 1.7% Institutions (89 holders) 8.9% Public and other holders 89.4%
HolderTypeShares% of sharesAs of
Bernd R. Seizinger
Director · +30,000 options
Insider 566,991 0.42% 2026-02-11
Wayne Pisano
Director · +30,000 options
Insider 492,414 0.36% 2026-02-12
Kirk Look
Chief Financial Officer · +260,000 options
Insider 287,515 0.21% 2026-02-12
Thomas Charles Heineman
Chief Medical Officer · +260,000 options
Insider 282,818 0.21% 2026-02-12
Seeds Investor LLC Institution (13F) 258,306 0.19% 2026-09-30
International Assets Investment Manageme Institution (13F) 201,510 0.15% 2026-09-30
Xtx Topco Ltd Institution (13F) 192,121 0.14% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 186,639 0.14% 2026-09-30
Angela Holtham
Director · +30,000 options
Insider 183,639 0.13% 2026-01-01
Larson Financial Group LLC Institution (13F) 168,323 0.12% 2026-09-30
Tocqueville Asset Management L.p. Institution (13F) 157,000 0.12% 2026-09-30
Pfg Investments, LLC Institution (13F) 144,758 0.11% 2026-09-30

Share count 136,140,469 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-06-01
filed 2026-06-03
Glover Stephen C.
Option award (A) 96,000 – –
2026-06-01
filed 2026-06-03
Brown Deborah Margaret
Option award (A) 30,000 – –
2026-06-01
filed 2026-06-03
RIGBY JONATHAN
Option award (A) 30,000 – –
2026-06-01
filed 2026-06-03
Pisano Wayne
Option award (A) 30,000 – –
2026-06-01
filed 2026-06-03
Holtham Angela
Option award (A) 30,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full ONCY picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ONCY and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.